Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis
Introduction: Hepatitis A virus (HAV) is a causative agent of acute hepatitis in humans, infecting more than one million individuals every year, including both symptomatic and asymptomatic infections. The currently available preventive vaccines for HAV are based on either wild-type or live-attenu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pasteur Institute of Iran
2023-09-01
|
| Series: | Journal of Medical Microbiology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://jommid.pasteur.ac.ir/article-1-568-en.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Hepatitis A virus (HAV) is a causative agent of acute hepatitis
in humans, infecting more than one million individuals every year, including
both symptomatic and asymptomatic infections. The currently available
preventive vaccines for HAV are based on either wild-type or live-attenuated
virus strains, which can contribute to the costliness of the vaccination
process. Therefore, it may be worthwhile to explore the potential of subunit
vaccines that utilize immunogenic viral products. Methods: This study
presents the results of a novel recombinant protein production study that
employed the native structures of HAV-VP1 and HBs-Ag. The fusion
protein underwent comprehensive characterization to evaluate its potential
applications in diagnostics and immunization. The truncated recombinant
protein, HAV-VP1 (position 99-259 aa) -HBs-Ag, was successfully
expressed in the Escherichia coli BL21-DE3 system. Results: The
recombinant protein, with a molecular weight of 46 kDa, was evaluated
using SDS-PAGE gel electrophoresis and confirmed by western blotting.
The fusion protein was successfully detected in serum samples positive for
HBV or HAV using anti-HBs and anti-VP1 antibodies. Additionally, it
elicited a potent humoral response in BALB/c mice. Conclusion: The novel
recombinant protein described in this study has the potential to serve as a
bivalent vaccine against HAV and HBV infections. The next step involves
evaluating the immunogenicity and safety profile of the protein. |
|---|---|
| ISSN: | 2345-5349 2345-5330 |